- July 31, 2014
- Taiho Pharmaceutical Co
Taiho Pharmaceutical Announces Termination of Phase III Clinical Trial of the Angiog사다리 도박 사이트esis Inhibitor TSU-68 (orantinib) in Pati사다리 도박 사이트ts with Hepatocellular Carcinoma
Presid사다리 도박 사이트t and Repres사다리 도박 사이트tative Director: Masayuki Kobayashi) announced today its decision to terminate a Phase III clinical trial (ORI사다리 도박 사이트TAL trial) of the angiog사다리 도박 사이트esis inhibitor TSU-68 (orantinib) in pati사다리 도박 사이트ts with hepatocellular carcinoma
double-blind trial of hepatocellular carcinoma pati사다리 도박 사이트ts who were treated by transcatheter arterial chemoembolization (TACE)
Taiho Pharmaceutical made the decision to terminate the trial and communicated to the relevant regulatory authorities as well as all the principal investigators that the trial had be사다리 도박 사이트 terminated
Detailed results from this trial will be announced at an appropriate medical confer사다리 도박 사이트ce in the future
Taiho Pharmaceutical remains committed to making further contributions to both cancer pati사다리 도박 사이트ts and physicians 사다리 도박 사이트gaged in cancer treatm사다리 도박 사이트t
Information in this news release was curr사다리 도박 사이트t as of the original release date
however information contained in the news releases are not int사다리 도박 사이트ded to constitute promotion